PE20180497A1 - Analogos de amilina - Google Patents

Analogos de amilina

Info

Publication number
PE20180497A1
PE20180497A1 PE2017001497A PE2017001497A PE20180497A1 PE 20180497 A1 PE20180497 A1 PE 20180497A1 PE 2017001497 A PE2017001497 A PE 2017001497A PE 2017001497 A PE2017001497 A PE 2017001497A PE 20180497 A1 PE20180497 A1 PE 20180497A1
Authority
PE
Peru
Prior art keywords
gly
lsstnvgsnt
lle
apr
refers
Prior art date
Application number
PE2017001497A
Other languages
English (en)
Inventor
Rasmus Just
Oliver Demmer
Lise Giehm
Jesper Sloth VILLADSEN
Henrik Kofoed Munch
Jolanta Skarbaliene
Maria Alexandrovna Deryabina
Dieter Wolfgang Hamprecht
Jesper Mosolff Mathiesen
Original Assignee
Zealand Pharma As
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52779493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20180497(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zealand Pharma As, Boehringer Ingelheim Int filed Critical Zealand Pharma As
Publication of PE20180497A1 publication Critical patent/PE20180497A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

SE REFIERE A ANALOGOS DE AMILINA DE FORMULA R1-Z-R2, EN DONDE R1 ES H, ACILO C1-4, BENZOILO, ENTRE OTROS; R2 ES OH O NHR3, DONDE R3 ES H O ALQUILO C1-3; Z ES UNA SECUENCIA DE AMINOACIDOS SELECCIONADA DE: RCNTATCATQRLADFLHRSSF-Gly(Me)-A-Ile(Me)-LSSTEVGSETP; RCNTATCATQRLADFLHRSSNNF-Gly(Me)-A-lle(Me)-LSSTNVGSNT-Apr; y RCNTATCATQRLAHFLHRSSNNF-Gly(Me)-A-lle(Me)-LSSTNVGSNT-Apr. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA UTIL EN EL TRATAMIENTO DE OBESIDAD, DIABETES
PE2017001497A 2015-03-18 2016-03-17 Analogos de amilina PE20180497A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15159737 2015-03-18

Publications (1)

Publication Number Publication Date
PE20180497A1 true PE20180497A1 (es) 2018-03-09

Family

ID=52779493

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017001497A PE20180497A1 (es) 2015-03-18 2016-03-17 Analogos de amilina

Country Status (19)

Country Link
US (2) US10766939B2 (es)
EP (1) EP3271381B1 (es)
JP (1) JP6769984B2 (es)
KR (1) KR20170126504A (es)
CN (1) CN107567459B (es)
AR (1) AR103954A1 (es)
AU (1) AU2016232218B2 (es)
BR (1) BR112017019378A2 (es)
CA (1) CA2979950A1 (es)
CL (1) CL2017002256A1 (es)
CO (1) CO2017008870A2 (es)
EA (1) EA035791B1 (es)
IL (1) IL253924A0 (es)
MX (1) MX2017011182A (es)
PE (1) PE20180497A1 (es)
PH (1) PH12017501674A1 (es)
SG (1) SG11201707286UA (es)
TW (1) TW201706294A (es)
WO (1) WO2016146739A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20180497A1 (es) 2015-03-18 2018-03-09 Zealand Pharma As Analogos de amilina
TWI784968B (zh) 2016-09-09 2022-12-01 丹麥商西蘭製藥公司 澱粉素類似物
PE20221168A1 (es) 2019-11-11 2022-07-25 Boehringer Ingelheim Int Agonistas del receptor npy2
JP2023522944A (ja) * 2020-04-20 2023-06-01 アイツーオー・セラピューティクス・インコーポレイテッド １型糖尿病患者に優れた血糖制御をもたらすためのヒトアミリンアナログポリペプチドの使用
CR20230074A (es) 2020-08-07 2023-04-19 Boehringer Ingelheim Int Agonistas del receptor npy2 solubles
PL4021929T3 (pl) 2020-09-24 2023-07-31 Gubra Aps Analogi ham15-52 z poprawioną si‎łą działania receptora amyliny (hamy3r)
WO2022248419A2 (en) 2021-05-22 2022-12-01 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
EP4144362A1 (en) 2021-09-06 2023-03-08 Adocia Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition
EP4129324A1 (en) 2021-08-02 2023-02-08 Adocia Compositions comprising at least an amylin receptor agonist and a glp-1 receptor agonist
CN113893349B (zh) * 2021-12-13 2022-07-22 北京大学第三医院（北京大学第三临床医学院） 达格列净及其类似物在制备防治雄性生殖功能障碍的药物中的用途
WO2023227133A1 (zh) * 2022-05-27 2023-11-30 杭州先为达生物科技股份有限公司 人胰淀素类似物、其衍生物及用途
WO2023232781A1 (en) * 2022-05-30 2023-12-07 Zealand Pharma A/S Liquid formulations of amylin analogues
WO2024022465A1 (zh) * 2022-07-29 2024-02-01 杭州九源基因工程有限公司 一种人胰淀素多肽衍生物及其用途

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175146A (en) 1989-12-05 1992-12-29 Vical, Inc. Synthetic calcitonin peptides
US5234906A (en) 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
SK88793A3 (en) * 1991-11-19 1994-12-07 Amylin Pharmaceuticals Inc Amylin agonising peptides and their using
KR100429966B1 (ko) 1993-09-07 2004-05-04 아밀린 파마슈티칼스, 인크. 위장 운동성 조절을 위한 제약 조성물
DE69737479T4 (de) 1996-08-30 2010-05-06 Novo Nordisk A/S Glp-1 derivate
DE69732640T2 (de) 1996-09-09 2006-01-12 Zealand Pharma A/S Festphasen-peptidsynthese
US5677279A (en) 1996-12-16 1997-10-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treating pain with amylin or agonists thereof
US7101853B2 (en) 1997-05-06 2006-09-05 Amylin Pharmaceuticals, Inc. Method for treating or preventing gastritis using amylin or amylin agonists
US7910548B2 (en) 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
WO1999034764A2 (en) 1998-01-09 1999-07-15 Amylin Pharmaceuticals, Inc. Amylin agonist pharmaceutical compositions containing insulin
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
EP1956000B1 (en) 1999-03-17 2016-10-05 Novo Nordisk A/S Acylating agents useful for acylating peptides
ES2425221T3 (es) 2003-05-30 2013-10-14 Amylin Pharmaceuticals, Llc Nuevos métodos y composiciones para suministro por vía transmucosa potenciado de péptidos y proteínas
CA2849552A1 (en) 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Llc Hybrid polypeptides with selectable properties
WO2006083254A1 (en) 2004-02-11 2006-08-10 Amylin Pharmaceuticals, Inc. Amylin family peptides and methods for making and using them
DE102004051014A1 (de) 2004-10-20 2006-04-27 Rwth Aachen Chemisch modifizierte Peptidanaloga
EP1922336B1 (en) 2005-08-11 2012-11-21 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
WO2007104789A2 (en) 2006-03-15 2007-09-20 Novo Nordisk A/S Amylin derivatives
AU2008216265B2 (en) 2007-02-15 2014-04-03 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
JP5385266B2 (ja) 2007-06-15 2014-01-08 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
EP2036539A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Stable formulations of amylin and its analogues
EP2036923A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Improved derivates of amylin
EP2340261B1 (en) 2008-10-21 2017-12-20 Novo Nordisk A/S Amylin derivatives
DK2370462T3 (da) 2008-12-15 2014-09-08 Zealand Pharma As Glucagon-analoger
UA104605C2 (uk) 2008-12-15 2014-02-25 Зіленд Фарма А/С Аналоги глюкагону
ES2477880T3 (es) 2008-12-15 2014-07-18 Zealand Pharma A/S Análogos del glucagón
MX2011006320A (es) 2008-12-15 2011-09-22 Zealand Pharma As Analogos de glucagon.
US8748375B2 (en) 2009-03-17 2014-06-10 Amylin Pharmaceuticals, Llc Methods for affecting body composition using amylin agonists
DK2454282T3 (en) 2009-07-13 2015-05-04 Zealand Pharma As acetylated glucagonanaloger
CN102639559B (zh) 2009-11-25 2015-04-29 诺沃—诺迪斯克有限公司 用于制备多肽的方法
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
WO2011160633A1 (en) 2010-06-24 2011-12-29 Zealand Pharma A/S Glucagon analogues
EP2718316B1 (en) * 2011-06-10 2019-12-04 Novo Nordisk A/S Polypeptides
PE20142113A1 (es) 2011-12-23 2014-12-03 Zealand Pharma As Analogos de glucagon
US8575091B1 (en) 2012-04-19 2013-11-05 Novo Nordisk A/S Amylin analogues and pharmaceutical compositions thereof
PL2838914T3 (pl) * 2012-04-19 2017-11-30 Novo Nordisk A/S Analogi ludzkiej amyliny
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
AR097701A1 (es) * 2013-09-19 2016-04-13 Zealand Pharma As Análogos de amilina
JP2016208556A (ja) * 2013-10-03 2016-12-08 三菱電機株式会社 デマンド予測装置及びデマンド予測方法
US10072060B2 (en) 2014-05-02 2018-09-11 The Research Foundation For The State University Of New York Islet amyloid polypeptides with improved solubility
CN106687474A (zh) 2014-09-04 2017-05-17 诺和诺德股份有限公司 新型胰淀素和降钙素受体激动剂
PE20180497A1 (es) 2015-03-18 2018-03-09 Zealand Pharma As Analogos de amilina
TWI784968B (zh) 2016-09-09 2022-12-01 丹麥商西蘭製藥公司 澱粉素類似物

Also Published As

Publication number Publication date
CN107567459A (zh) 2018-01-09
AU2016232218B2 (en) 2020-09-10
US10766939B2 (en) 2020-09-08
MX2017011182A (es) 2018-06-06
KR20170126504A (ko) 2017-11-17
EP3271381B1 (en) 2021-09-08
IL253924A0 (en) 2017-10-31
BR112017019378A2 (pt) 2019-02-19
TW201706294A (zh) 2017-02-16
EA035791B1 (ru) 2020-08-11
CO2017008870A2 (es) 2017-11-10
EA201791617A1 (ru) 2018-02-28
PH12017501674A1 (en) 2018-03-12
AR103954A1 (es) 2017-06-14
JP6769984B2 (ja) 2020-10-14
AU2016232218A1 (en) 2017-09-21
SG11201707286UA (en) 2017-10-30
CL2017002256A1 (es) 2018-04-02
US20160272693A1 (en) 2016-09-22
EP3271381A1 (en) 2018-01-24
JP2018510871A (ja) 2018-04-19
US20210115104A1 (en) 2021-04-22
CA2979950A1 (en) 2016-09-22
WO2016146739A1 (en) 2016-09-22
CN107567459B (zh) 2021-09-24

Similar Documents

Publication Publication Date Title
PE20180497A1 (es) Analogos de amilina
PE20171322A1 (es) Dinucleotidos ciclicos utiles para el tratamiento del cancer entre otros
PE20150627A1 (es) Derivados de c17-alcandiilo y alquendiilo del acido oleanolico y sus metodos de uso
CL2016000873A1 (es) Analogos de glucagon acilado, una composicion que lo comprende; su uso para la fabricacion de un medicamento util para impedir el aumento de peso; un kit y un procedimiento.
PE20142452A1 (es) AMIDAS CICLICAS COMO INHIBIDORES DE MetAP-2
BR112018006920A2 (pt) agonistas dos receptores de glucagon
BR112018075140A2 (pt) composição na forma de uma solução aquosa injetável, e, formulação de dose única a um ph de 7 a 7,8
BR112018075259A2 (pt) composição na forma de uma solução aquosa injetável, cujo ph é de 6,0 a 8,0
EA201691259A1 (ru) РЕГУЛЯТОРЫ Nrf2
PE20130281A1 (es) Derivados de acido 5-alquinil-3-amida-2-tiofeno-carboxilico como inhibidores del virus flaviviridae
EA201790024A1 (ru) Модуляторы toll-подобных рецепторов для лечения вич
CL2018000688A1 (es) Compuestos heterociclicos que contienen bencilamina y composiciones útiles contra infección por micobacterias
PE20142098A1 (es) Compuestos terapeuticamente activos y sus metodos de uso
AR094966A1 (es) Composiciones farmacéuticas para el tratamiento de infecciones hcv
MX363457B (es) Compuestos de sulfonamida heterociclica sustituida utiles como moduladores del canal del receptor de potencial transitorio a1 (trpa1).
PE20150224A1 (es) Inhibidores del nampt
ECSP18061667A (es) Pirimidinas sustituidas con arilo para su uso en la infección por virus influenza
EA201400827A1 (ru) Материалы и способы лечения диареи
EA201400537A1 (ru) 18-МЕТИЛ-6,7-МЕТИЛЕН-3-ОКСО-17-ПРЕГН-4-ЕН-21,17β-КАРБОЛАКТОНЫ, ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ СОЕДИНЕНИЯ, И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ ЭНДОМЕТРИОЗА
CL2018002089A1 (es) Maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus procesos de preparación y su uso
CR20130501A (es) Derivados novedosos de cefalosporinas y composiciones farmacéuticas de estos
PE20161444A1 (es) 1,2-ciclopentanos sustituidos como antagonistas del receptor de orexina
EA201790570A1 (ru) Модуляторы р2х7
EA201700504A1 (ru) 5-ароматическое алкинилзамещенное бензомидное соединение и способ его получения, фармацевтическая композиция и их применение
PE20171622A1 (es) Formulacion de relacion fija de insulina glargina/lixisenatida